Epilepsy

The co-director of the Jane and John Justin Neurosciences Center at Cook Children’s Hospital discussed the real-world data collected from the Expanded Access Program for fenfluramine (Fintepla; Zogenix) in patients with Dravet syndrome.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 24, 2020.

The initial report of the US Expanded Access Program for fenfluramine indicates that those with Dravet syndrome treated with fenfluramine (Fintepla; Zogenix) have clinically meaningful responses similar to that observed in clinical trials.

Researchers found multiple measure correlations between perampanel use and reductions in Insomnia Severity Index scores in those who had comorbid epilepsy and anxiety.

Retrospectively analysis data suggest that while the majority of epileptics have no significant worsening in bone mineral density, they maintain an amplified risk of suffering major osteoporotic fractures.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 17, 2020.

Data out to 11 years suggest that individualized doses of brivaracetam (Briviact; UCB Pharma) are safe and effective in reducing focal and primary generalized seizures.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 10, 2020.

Elizabeth Thiele, MD, PhD, answers a variety of questions on treating tuberous sclerosis, and the landscape of treatments available at this time.

Significant advancements in genetics and the implementation of artificial intelligence have begun to carve a new, more personalized path for the diagnosis and treatment of seizure disorders.

The director of epilepsy research and epilepsy clinical trials at NYU Langone Health’s Comprehensive Epilepsy Center spoke about the recent study findings from a trial of Staccato alprazolam.

The >50% responder rate was similar between children and adults according to data from a meta-analysis of 7 clinical trials of topiramate, perampanel, and lamotrigine.

Neurology News Network for the week ending April 4, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 3, 2020.

NeurologyLive’s parent company, MJH Life Sciences, will be hosting the virtual MJH Life Sciences Sleeves Up Blood Drive from March 31 through April 30.

The agency has assigned a PDUFA date of July 31, 2020, for the purified CBD treatment which has been previously approved for Dravet and Lennox-Gastaut syndromes.

Pediatric patients with focal-onset seizures experienced significant reductions in their 24-hour seizure rates compared to placebo when administered adjunctive 14 mg/kg per day pregabalin (Lyrica; Pfizer).

Full data from the ARCADE study of Ovid’s soticlestat is expected to be released in the first quarter of 2021.

The president and CEO of Engage Therapeutics, along with the company’s executive VP and COO, discussed its investigational Staccato alprazolam product in the abortive treatment of seizures.

The chief medical officer at SK Life Science discussed what the clinical community needs to know with cenobamate headed to the market in the second quarter of this year.

Eton Pharmaceuticals plans to submit a new drug application for ET-101 in the third quarter of 2020, anticipating its formulation to be the first approved oral topiramate solution.

Results from a study of 55 patients with temporal lobe epilepsy who underwent surgery suggest that resection may result in hippocampal atrophy and memory decline as a result of disruption of a memory network that includes the temporal lobe.

The webinar, a partnership between Women Neurologist's Group (WNG) and NeurologyLive, features the latest updates from CMS on billing and coding for telemedicine visits.

As neurologists and other specialists may increasingly be called upon to serve as general hospitalists in the wake of the COVID-19 pandemic, keeping health care workers healthy becomes paramount.

The Tuberous Sclerosis Alliance (TS Alliance) have prepared an FAQ to address concerns from the tuberous sclerosis complex (TSC) community regarding the COVID-19 outbreak.

Neurology News Network for the week ending March 14, 2020.

The Engage Therapeutics product met its primary end point in the StATES study, with an onset of action for ceasing seizure activity of approximately 30 seconds, on average.

SK Life Science’s newly approved treatment for partial-onset seizures is set to launch in the second quarter of 2020, after being designated Schedule V by the DEA.

Despite the introduction of second-generation ASMs, drug tolerability has been relatively unchanged over the last 30 years.

Both the 10- and 20-mg doses were associated with clinically relevant reductions in convulsive seizures with a favorable safety and tolerability profile.